Combination drug strategy produces promising results by hyperactivating oncogenic signaling

FGF2 impairs cell cycle progression in K-Ras-driven cancer cells. Serum-starved Y1D1 cells were stimulated by 10% serum with or without 10 ng·mL?1 FGF2 to re-entry the cell cycle. Cells were subjected to a BrdU pulse 30 min before sample collection (every two hours). Credit: Cancer Discovery (2024). DOI: 10.1158/2159-8290.CD-23-0216 A combination of two drugs was capable of suppressing tumors in a non-conventional manner. Instead of inhibiting tumor cell division, as the most widely used medications do, the strategy consisted of hyperactivating oncogenic signaling by these cells to the point where they became stressed. The other drug then attacked the stressed Read More